GlassScriptPhysician profile
April Maiyo
NPI 1528717659
$4,623.41
in general payments reported to CMS, 2019-2025
48 companies · $1,435 in 2025
The $1,435 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,056 · 2023: $867 · 2024: $1,265 · 2025: $1,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,567.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $593.48 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $390.58 | 2022-2025 | |
| Abbvie INC. | $344.90 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $337.29 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $265.88 | 2022-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $252.98 | 2022-2025 | |
| Corcept Therapeutics | $236.00 | 2022-2024 | Korlym |
| Calliditas Therapeutics US INC. | $167.45 | 2025 | Tarpeyo |
| Shield Therapeutics INC | $145.27 | 2024-2025 | |
| Amgen INC. | $119.82 | 2022-2025 | Tavneos, Evenity, Prolia |
| Lundbeck LLC | $109.20 | 2024 | Rexulti |
| Ardelyx, INC. | $107.86 | 2024-2025 | Ibsrela |
| Travere Therapeutics, INC. | $103.04 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $92.72 | 2025 | Keveyis, Gvoke Hypopen, Recorlev |
| Merck Sharp & Dohme LLC | $90.85 | 2022-2023 | Steglatro, Belsomra, Steglujan |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Maiyo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.